According to @demishassabis on Bloomberg Tech Europe, Isomorphic Labs is leveraging artificial intelligence to design new drug candidates that address challenging medical targets. The discussion with ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...

Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI. The news comes as tech ...

To “cure all diseases” someday, Isomorphic Labs is ready to begin human trials of its AI-designed drugs. Artificial intelligence has a terrible reputation among the general public for many reasons, ...

In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed ...

In today’s rapidly evolving digital landscape, JavaScript has firmly established itself as a cornerstone of web development. With an expansive ecosystem of frameworks at developers’ disposal, ...

On a rare sunny day in London at the Google DeepMind office, Colin Murdoch saw the bank deposit from his employer come through. It wasn't his paycheck. Google was investing in his startup. The ...

Stream NBC 5 for free, 24/7, wherever you are. On a rare sunny day in London at the Google DeepMind office, Colin Murdoch saw the bank deposit from his employer come through. It wasn't his paycheck.

On a rare sunny day in London at the Google DeepMind office, Colin Murdoch saw the bank deposit from his employer come through. It wasn't his paycheck. Google was investing in his startup. Get top ...

eSpeaks’ Corey Noles talks with Rob Israch, President of Tipalti, about what it means to lead with Global-First Finance and how companies can build scalable, compliant operations in an increasingly ...

London-based Isomorphic Labs, an AI-focused drug design and development company, has raised $600M (nearly €555.44M) in its first external funding round. The round is led by Thrive Capital, with ...